DMK Pharmaceuticals Corporation
DMKPQOTCHealthcare
$0.00
+$0.00(+0.00%)
Market Cap$1010
P/E Ratio—
52W High$0.001
52W Low$0.00001
DMK Pharmaceuticals Corporation (DMKPQ) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · DMKPQ · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 | 2018-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($26.20M) | ($34.60M) | ($35.85M) | ($27.51M) | ($39.01M) |
| Depreciation & Amort. | $1.48M | $1.43M | $2.33M | $2.96M | $3.10M |
| Stock-Based Comp. | ($0.34M) | $1.98M | $4.10M | $5.87M | $0.00M |
| Change in Working Capital | ($1.34M) | ($10.80M) | $6.97M | ($0.62M) | ($6.54M) |
| Net Cash from Operations | ($25.90M) | ($37.79M) | ($20.90M) | ($19.89M) | ($32.66M) |
| Investing Activities | |||||
| Capital Expenditure | ($0.68M) | ($1.22M) | ($0.70M) | ($2.87M) | ($3.54M) |
| Purchases of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Sales of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Investing | $3.48M | $0.28M | ($0.95M) | ($2.87M) | ($3.54M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | $1.77M | $3.19M | ($0.50M) | ($0.49M) |
| Net Cash from Financing | $0.28M | $53.94M | $19.89M | $12.29M | $37.13M |
| Free Cash Flow | |||||
| Free Cash Flow | ($26.58M) | ($39.01M) | ($21.60M) | ($22.75M) | ($36.19M) |
| FCF Margin %(computed) | -558.88% | — | -778.00% | -102.89% | -239.90% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more DMK Pharmaceuticals Corporation data
About DMK Pharmaceuticals Corporation (DMKPQ) Cash Flow Statement
DMK Pharmaceuticals Corporation generated operating cash flow of ($0.03B) and free cash flow of ($0.03B) for 2022 — a FCF margin of -558.88%. Capital expenditure was ($0.00B).
Frequently asked questions
DMKPQ · 4 questionsDMK Pharmaceuticals Corporation generated free cash flow of ($0.03B) for 2022, up 31.9% year-over-year.
DMKPQ free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10